ArticleBMC microbiology2025
High-throughput single-cell analysis reveals fully human Omp38-specific monoclonal antibodies against Acinetobacter baumannii.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Human antibodies as emerging drugs for antimicrobial resistance.Trends in immunology · 2026Review
- The Role of Combination Antibiotic Therapy in Combatting Drug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAcinetobacter baumannii (A. baumannii) is a significant global health threat, particularly in hospital environments, where it is often linked to severe infections. As the need for innovative therapeutic approaches grows, fully human monoclonal antibodies (mAbs) have gained attention because of their high specificity, reduced immunogenicity, and enhanced affinity for target antigens, which may improve clinical efficacy.
methodsUsing the Beacon platform, we isolated single B cells from immunized humanized genomic orthologs for antibody development (HUGO-Ab) mice to develop outer membrane protein (OMP)-specific mAbs. The variable regions of the selected mAbs were cloned into mammalian expression vectors containing constant human IgG1 regions to generate fully human mAbs. After identifying mAbs binding to Omp38 via ELISA, their binding ability to LAC-4 and the clinical isolates was further evaluated. Subsequently, the effects of these mAbs on A. baumannii adhesion and biofilm formation were tested, and their protective efficacy was assessed using a lethal infection model. Finally, bioinformatics methods were used to predict the binding conformation of mAb F2 to Omp38.
resultsOmp38-specific fully human mAb F2 potently and broadly bound to A. baumannii strains and inhibited bacterial adherence and biofilm formation. Binding modeling and conformational analysis revealed that F2 targets the extracellular region of Omp38 and forms stable hydrogen bonds with different strains, suggesting its potential for broad-spectrum binding to diverse A. baumannii strains.
conclusionsThis study demonstrates the utility of high-throughput single-cell analysis and antibody engineering in developing fully human mAbs against A. baumannii, highlighting the potential of these novel fully human mAbs to advance therapeutic strategies and improve clinical outcomes for A. baumannii infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.